747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-747-P

By:

• POLONSKY, WILLIAM H.;
• MCCRIMMON, RORY J.;
• WHITMIRE, KATHERINE H.;
• GIORGINO, FRANCESCO;
• CHEN, JUNG-FU;
• NICHOLLS, CHARLIE;
• LEW, ELISHEVA;
• ALVAREZ, AGUSTINA;
• COUDERT, MATHIEU;
• ROSENSTOCK, JULIO

Publication type:

Article